POLE and endometrial cancer: Although in lower percentages than in endometrial cancer, in ovarian cancer there are also cases exhibiting a POLE mutation and dMMR status [66,68], thereby the presence of these alterations could determine a niche to offer ICIs in ovarian cancer.